Topical Wound Oxygen Therapy Proven Cost-Effective for Chronic Diabetic Foot Ulcers
A recent study published in the Journal of Diabetes and Its Complications evaluates the cost-effectiveness of Topical Wound Oxygen (TWO2) therapy for chronic diabetic foot ulcers (DFUs). Utilizing a Markov model over a two-year horizon, the research assesses both economic and clinical outcomes associated with TWO2 therapy compared to standard care. Read the full article.
Key Highlights:
- Economic Benefits: The study indicates that, at a weekly cost of £650 for up to 12 weeks, TWO2 therapy results in a £5,038 reduction in total diabetic foot care costs over two years per patient compared to standard care.
- Improved Health Outcomes: Patients receiving TWO2 therapy experienced an increase of 0.07 quality-adjusted life years (QALYs) over the two-year period.
- High Probability of Cost-Effectiveness: Probabilistic sensitivity analysis reveals an 81% likelihood that TWO2 therapy is cost-effective at a willingness-to-pay threshold of £25,000 per QALY.
- Clinical Efficacy: The model’s clinical inputs are derived from a multinational randomized controlled trial demonstrating superior healing rates with TWO2 therapy.
- Global Health Implications: Given the substantial burden of DFUs worldwide, the adoption of cost-effective treatments like TWO2 therapy could significantly reduce healthcare expenditures and improve patient quality of life.
This study underscores the potential of TWO2 therapy not only to enhance clinical outcomes for patients with chronic DFUs but also to provide significant cost savings for healthcare systems.
Read the full article on the Advanced Oxygen Therapy Inc. website.
Keywords:
Topical Wound Oxygen Therapy,
diabetic foot ulcers,
cost-effectiveness,
quality-adjusted life years,
health economics